Junín Virus mAb
Argentine hemorrhagic fever
Pre-clinicalActive (based on published research)
Key Facts
Indication
Argentine hemorrhagic fever
Phase
Pre-clinical
Status
Active (based on published research)
Company
About Mapp Biopharmaceutical
Mapp Biopharmaceutical is a private, clinical-stage biotech focused on developing monoclonal antibody countermeasures against deadly viral threats like Nipah, Marburg, and Junín viruses. The company leverages strategic partnerships, notably with BARDA, to advance its pipeline through non-clinical and clinical development. With a mission-driven approach to global health and biodefense, Mapp is progressing multiple candidates, including one now in human trials for Nipah virus, positioning it as a key player in the preparedness and response landscape for emerging infectious diseases.
View full company profile